
Tuesday, November 08, 2022 12:04:41 PM
The price per share $294.845 +$17.82 (+6.43%)
Volume 3,390,182
https://stockcharts.com/h-sc/ui?s=AMGN
Amgen's Olpasiran Reduced Cholesterol Levels In 95% Of Patients In Mid-Stage Study
By Benzinga — 10:01 AM ET 11/07/22
Amgen Inc (NASDAQ:AMGN) presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of olpasiran (formerly AMG 890) in adults with elevated lipoprotein levels and a history of atherosclerotic cardiovascular disease (ASCVD).
These data were presented during the Nov. 6 Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions.
Patients who received 75 mg or higher every 12 weeks had a 95% or greater reduction in lipoprotein levels compared to placebo at week 36.
Related: Amgen Reports Q3 Higher Profit, Despite Slight Fall In Topline Growth.
At these doses (75 mg or higher), more than 98% of patients achieved a lipoprotein level of 125 nmol/L or less at week 36.
Overall, the rates of adverse events were similar in the olpasiran and placebo arms. The most common treatment-related adverse events were injection site reactions, primarily pain.
At week 36, lipoprotein levels increased by a mean of 3.6% in the placebo arm, whereas there were substantial reductions of Lp(a) levels in all of the olpasiran arms.
Placebo-adjusted mean percent reductions were 70.5% for 10 mg every 12 weeks, 97.4% for 75 mg every 12 weeks, 101.1% for 225 mg every 12 weeks, and 100.5% for 225 mg every 24 weeks.
Price Action: AMGN shares are up 0.90% at $271.47 on the last check Monday.
Recent AMGN News
- AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS • PR Newswire (US) • 03/08/2025 11:00:00 AM
- AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS • PR Newswire (US) • 03/08/2025 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2025 01:09:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2025 01:08:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2025 01:07:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2025 01:06:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2025 01:06:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2025 01:05:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2025 12:58:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2025 12:57:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2025 12:56:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2025 12:55:21 AM
- AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND • PR Newswire (US) • 03/04/2025 09:54:00 PM
- POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS • PR Newswire (US) • 03/01/2025 10:30:00 PM
- AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE • PR Newswire (US) • 02/28/2025 09:01:00 PM
- Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 • PR Newswire (US) • 02/27/2025 03:10:00 PM
- Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 • PR Newswire (US) • 02/27/2025 03:04:00 PM
- Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 • PR Newswire (Canada) • 02/27/2025 03:04:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2025 01:07:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2025 01:06:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/21/2025 09:27:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2025 01:59:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/19/2025 09:18:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/19/2025 09:14:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/19/2025 07:25:37 PM
FEATURED Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 • Mar 10, 2025 9:05 AM
North Bay Resources Announces Assays up to 5.69% Copper, 1 Opt. Silver, and 0.22% Vanadium at Copper Island Project, British Columbia • NBRI • Mar 10, 2025 9:00 AM
Avant Technologies and JV Partner, Ainnova, Strategically Align with Apollo Hospitals to Advance AI in Healthcare • AVAI • Mar 10, 2025 8:00 AM
Veri Medtech (VRHI) Network Grows To 400 Physicians • VRHI • Mar 10, 2025 7:32 AM
One World Products' Isiah Thomas Issues Investor Update • OWPC • Mar 6, 2025 9:19 AM
Authentic Holdings To Reduce Debt by over $2 Million While Achieving Substantial Revenue Growth • AHRO • Mar 6, 2025 8:00 AM